Mandy Jongeneelen

Johnson & Johnson (Israel) — Israel

Medicine · Health Sciences

21h-index5.7kcitations27works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Influenza Virus Research Studies(11), Monoclonal and Polyclonal Antibodies Research(10), SARS-CoV-2 and COVID-19 Research(6), Respiratory viral infections research(5), COVID-19 Clinical Research Studies(4)

Publications27 total

VHH antibody loop guides design of a synthetic macrocyclic peptide that potently blocks influenza virus membrane fusion
npj Viruses·2025Open Access
De novo design of D-peptide ligands: Application to influenza virus hemagglutinin
Proceedings of the National Academy of Sciences·2025· 4 citedOpen Access
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
Nature Communications·2024· 9 citedOpen Access
Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen
npj Vaccines·2023· 6 citedOpen Access
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
Vaccine·2022· 32 citedOpen Access
Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions
Proceedings of the National Academy of Sciences·2022· 48 citedOpen Access
LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
Open Forum Infectious Diseases·2021Open Access
Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
2021· 49 citedOpen Access
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP
The Journal of Experimental Medicine·2021· 69 citedOpen Access
A small-molecule fusion inhibitor of influenza virus is orally active in mice
Science·2019· 143 cited
Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin
Science·2018· 223 cited
A common solution to group 2 influenza virus neutralization
Proceedings of the National Academy of Sciences·2013· 190 citedOpen Access
Highly Conserved Protective Epitopes on Influenza B Viruses
Science·2012· 882 citedOpen Access
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
Science·2011· 853 citedOpen Access
Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step
Journal of Virology·2009· 103 citedOpen Access
Antibody Recognition of a Highly Conserved Influenza Virus Epitope
Science·2009· 1.3k citedOpen Access
Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells
PLoS ONE·2008· 743 citedOpen Access
Isolation and Characterization of Human Monoclonal Antibodies from Individuals Infected with West Nile Virus
Journal of Virology·2006· 175 citedOpen Access
The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries
European Journal of Immunology·2005· 94 citedOpen Access
Affinity ranking of antibodies using flow cytometry: Application in antibody phage display-based target discovery
Journal of Immunological Methods·2005· 44 cited
page 1 of 2Next →

Frequent Co-authors

Jaap Goudsmit(14), Boerries Brandenburg(12), Mark Throsby(10), Robert H. Friesen(8), Ian A. Wilson(8), Ronald Vogels(8), John de Kruif(8), Jarek Juraszek(6), Freek Cox(5), Alexander B. H. Bakker(5), Therèse Visser(5), Wilfred E. Marissen(5), Hanneke Schuitemaker(5), Damian C. Ekiert(4), Leo L. M. Poon(4), Wouter Koudstaal(4), Arjen Q. Bakker(4), Sven Blokland(4), Jan Vermond(4), Marieke Clijsters-van der Horst(4)